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In the last World Alzheimer Report the global economic 
impact of Alzheimer’s Disease (AD) and dementias was 
estimated to be US$818 billion, with 47 million people 
suffering from AD and representing the 0.5% of the 
global population [1]. Despite the urgent need for 
interventions, currently there are no available therapies 
with the ability to modify the clinical course of AD. No 
tailored drugs for AD have been approved over the past 
15 years, despite massively expensive trials aimed at 
tackling the disease. An often-cited explanation for the 
clinical trials’ failure is that they are set too late in the 
disease course. The cholinergic hypothesis of AD has 
been extensively investigated and prompted the current 
use of anticholinesterase inhibitors, whose efficacy is 
however extremely limited. It has been recently put 
forward the hypothesis that other neurotransmitter 
pathways are involved in AD pathophysiology with a 
special focus on the monoaminergic systems [2-4]. A 
recent work in a transgenic mice, harbouring human 
Amyloid Precursor Protein (APP) mutant allele linked 
to familial AD, demonstrated that degeneration of 
dopaminergic neurons in the ventral tegmental area 
(VTA) precedes the deposition of Aβ-plaques in the 
hippocampus [2]. VTA is a brainstem nucleus contain-
ing dopaminergic neurons that project diffusively to the 
brain cortex by direct and indirect pathways [2]. 
Interestingly, an association between measures of VTA 
disruption and memory impairment was previously 
shown in patients with early AD [3]. The dopaminergic 
system is known to be implicated in several cognitive 
and behavioural functions [5] and, importantly, may be 
modulated by pharmacological interventions [5]. Beha-
vioural symptoms are known to be present since the 
early clinical stages of AD [6]. They strongly impact on 
patients’ global disability by causing high distress for 
the patients themselves and their caregivers. Against 
this background we recently investigated the potential 
relationship between disruption of VTA projections and 
behavioural disorders in patients with AD at different 
clinical stages [4]. We used functional brain magnetic 
resonance imaging (MRI) at rest, which has been 
previously shown to be highly sensitive to AD patho-
logy [7], to selectively investigate the VTA-driven 
modulation of connectivity in AD brains and its impact 
on behavioural symptoms. Strikingly, when comparing 
AD patients to controls, we identified a pattern of dis-
connection between VTA and the rest of  the  brain  that 
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that resembled the so-called default-mode network, with 
a progressive disruption from early to severe stages of 
disease. This network, which is known to be selectively 
targeted by AD pathology, is implicated not only in 
cognition but also in affective functions, thus 
accounting for the whole symptomatic spectrum of AD. 
In our large cohort of patients, the vast majority of them 
presented with behavioural symptoms regardless of 
their clinical stage. Among clinical symptoms, the 
presence and severity of aggression, irritability, and 
sleep and eating disorders were proven being directly 
associated to a disruption of VTA connectivity in areas 
of the brain that are known to be implicated in 
behaviour. Together with previous findings [2,3], this 
study further highlights the importance of the 
dopaminergic system as an early contributor to AD 
progression with a specific focus on behavioural symp-
toms. With respect to the neurotransmitters potentially 
involved in AD pathophysiology, the relationship 
between cholinergic and dopaminergic dysfunction still 
needs to be further clarified. It is possible that the 
involvement of these two pathways is only part of a 
more complex pathophysiological picture, with indivi-
dual contributions that may impact differently at 
different disease stages. This opens novel therapeutic 
perspectives that need to be explored and tested in 
clinical trials. Furthermore, this stresses the importance 
of multidimensional research projects that combine 
basic/animal models to translational studies in humans.  
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